不同膀胱灌注疗法预防浅表性膀胱癌术后复发及对血清VEGF影响的临床观察

发布时间：2018-01-02 01:17

本文关键词：不同膀胱灌注疗法预防浅表性膀胱癌术后复发及对血清VEGF影响的临床观察　出处：《中国现代医学杂志》2015年04期 　论文类型：期刊论文

【摘要】：目的研究不同膀胱灌注疗法治疗浅表性膀胱癌术后患者的疗效及对血清VEGF含量的影响。方法将该院泌尿外科接受经尿道电切术的120例浅表性膀胱癌患者纳入研究,根据术后灌注治疗的方法不同分为两组,观察组患者接受改良长期灌注疗法,对照组患者接受短期灌注疗法,比较两组患者尿液中肿瘤标志物水平、复发率、毒副反应以及血清VEGF含量。结果观察组患者尿液中的NMP22、CYFR21-1和BTA含量以及血清中VEGFA、VEGFB和VEGFC的含量低于对照组(P0.05)。观察组患者的术后复发率低于对照组(P0.05)。治疗过程中,两组患者的毒副反应发生率无差异(P0.05)。结论改良长期灌注疗法有助于彻底杀灭肿瘤细胞,降低远期复发率,减弱膀胱癌的血管新生能力,且毒副反应较轻。
[Abstract]:Objective to study the effects of intravesical therapy for superficial bladder cancer after surgery in patients with clinical efficacy and effect on serum VEGF content. Methods the hospital department of Urology received transurethral resection in 120 cases of superficial bladder cancer were included in the study according to the method of perfusion therapy after operation were divided into two groups, patients in the observation group an improved long-term perfusion therapy, the control group received short-term infusion therapy, compared two groups of patients with urinary tumor markers, recurrence rate, adverse reaction and serum VEGF content. Results in the observation group, urine NMP22, CYFR21-1 and the content of BTA and VEGFA in serum, the content of VEGFB and VEGFC lower than the control group (P0.05). The observation group of patients with postoperative recurrence rate than the control group (P0.05). The course of treatment, adverse reaction in the two groups there was no difference (P0.05). Conclusion the improved long-term perfusion therapy helps to completely kill tumor Cells, reduce the long-term recurrence rate, weaken the angiogenesis of bladder cancer, and the toxic and side effects are mild.

【作者单位】：湖北医药学院附属人民医院泌尿外科;
【分类号】：R737.14
【正文快照】： 浅表性膀胱癌是局限于黏膜层和黏膜下层、而不侵犯基层的肿瘤,多采用经尿道电切术进行治疗。流行病学资料显示,超过50%的浅表性膀胱癌患者会在术后2~3年内发生复发[1];而通过膀胱内灌注化疗药物可以有效的降低膀胱癌复发率。吡柔比星是一类对于膀胱癌细胞具有极高敏感性的化疗

【相似文献】